Pacific Biosciences of California Inc（PACB）财务数据PACBPacific Biosciences of California Inc

Pacific Biosciences of California, Inc. (PACB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumable revenue, accounting for 51.6% of total sales, equivalent to $20.11M. Other significant revenue streams include Instrument revenue and Service And Other. Understanding this composition is critical for investors evaluating how PACB navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Pacific Biosciences of California, Inc. maintains a gross margin of 30.26%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -114.36%, while the net margin is -114.70%. These profitability ratios, combined with a Return on Equity (ROE) of -929.32%, provide a clear picture of how effectively PACB converts its operational activities into shareholder value.

In the context of the broader market, PACB competes directly with industry leaders such as TCMD and SSII. With a market capitalization of $665.18M, it holds a leading position in the sector. When comparing efficiency, PACB's gross margin of 30.26% stands against TCMD's 75.50% and SSII's 48.46%. Such benchmarking helps identify whether Pacific Biosciences of California, Inc. is trading at a premium or discount relative to its financial performance.

Pacific Biosciences has reported a decline in revenue, with Q2 2026 revenue at $39 million, a slight decrease from $39.8 million in Q2 2025. The company has also posted significant net losses, including a loss of $0.14 per share in Q2 2026, which missed Wall Street estimates.